David R. Bauer
Advises on healthcare, life sciences and technology transactions, including strategic licensing and collaboration agreements and M&A. A 2023 Law360 Life Sciences MVP.
David advises clients on a wide range of IP and technology-related corporate and commercial transactions, including licensing and collaboration agreements, R&D agreements, supply and distribution agreements, and other strategic commercial and partnering agreements. He also advises on the IP and technology-related aspects of M&A transactions, joint ventures, financings, restructurings and capital markets offerings.
With a bioscience-related Ph.D., David has extensive experience and a particular focus advising clients in the pharmaceutical, biotechnology and medical device industries. His life sciences experience spans transactions across the world related to small molecule pharmaceuticals, biologics, cellular and gene therapies, diagnostics and medical devices. David also regularly advises clients in a variety of other industries, such as IT, media and financial services.
David is a 2023 Law360 “Life Sciences MVP of the Year” and an IAM Patent 1000 recommended IP lawyer.
Experience
Healthcare & Life Sciences
- GSK – collaboration with Flagship Pioneering; option and license agreement with Boston Pharmaceuticals; acquisition of Affinivax
- Roche – acquisitions of Spark Therapeutics, InterMune, Flatiron Health, Promedior, Adheron Therapeutics and Tensha Therapeutics; collaboration with Foundation Medicine; option to acquire and collaboration with Janus Biotherapeutics; acquisition of LumiraDx’s point of care technology platform
- Bristol Myers Squibb – acquisition of Forbius; divestitures of rights to Lysodren, Nystatin, Sotalex and Questran to various acquirers
- Gilead Sciences – acquisitions of Immunomedics, MiroBio and CymaBay Therapeutics
- Novartis – acquisition of worldwide therapeutic rights for Fibroblast Activation Protein targeting agents from iTheranostics (an affiliate of SOFIE Biosciences), which are licensed from the University of Heidelberg
- BVF Partners LP on MoonLake Immunotherapeutics’ exclusive in-license of Sonelokimab from Merck KGaA
- Roivant Sciences – combination with a SPAC
- AC Immune – option and license agreement with Takeda; collaboration with Eli Lilly; collaboration with Biogen
- Shionogi – collaboration with Sage Therapeutics
- Novo Nordisk – acquisitions of Dicerna Pharmaceuticals, Forma Therapeutics, Corvidia Therapeutics and Emisphere Technologies; acquisition of U.S. and Canadian rights to Macrilen from Strongbridge Biopharma; pending acquisition of certain Catalent sites from Novo Holdings
- Freeline Therapeutics – commercial manufacturing arrangement with Brammer Bio
- Charles River Laboratories – acquisitions of Cognate BioServices, HemaCare and Vigene Biosciences
- Y-mAbs – license agreement with SciClone for DANYELZA® and Omburtamab in China
- Shire – acquisitions of NPS Pharmaceuticals, Foresight Biotherapeutics and Lotus Tissue Repair; sale of mRNA platform to Translate Bio; sale of oncology business to Servier
- IPOs of AC Immune, ADC Therapeutics, Denali Therapeutics, Editas Medicine, Freeline Therapeutics, Royalty Pharma and Vaccitech
Technology and Industrials
- Comcast on its acquisition of Icontrol Networks
- Ocado Group on its acquisitions of Haddington Dynamics and Kindred Systems
- Bridgepoint Capital acquisition of Sun World International
Pro Bono
- Intellectual property advice to Groundswell Community Mural Project (for which he won a Lawyers Alliance of New York Cornerstone Award)
Insights
Recognition
Law360 – “Life Sciences MVP of the Year,” 2023
IAM Patent 1000 – “The go-to for pharmaceutical and biotech deals and collaborations is bioscience PhD David Bauer.”
Education
- magna cum laude
- Order of the Coif
- Senior Articles Editor, Fordham Law Review
- with honors
Clerkships
Qualifications and admissions
- State of New York
- U.S. Court of Appeals, Tenth Circuit